OncoMatch/Clinical Trials/NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Is NCT04918186 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for ovarian cancer.
Treatment: Durvalumab · BA3011 · BA3021 · ENB003 · Toripalimab — This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy
Cannot have received: cytotoxic chemotherapy
Exception: no more than one cytotoxic chemotherapy regimen for platinum-resistant disease
patients may not have received more than one cytotoxic chemotherapy regimen for platinum-resistant disease
Lab requirements
Blood counts
Absolute neutrophils ≥ 1.5 x 10^9/L (1500/µL); Platelets ≥ 100 x 10^9/L (100,000/µL); Hemoglobin ≥ 90g/L (10.0 g/dL) with no blood transfusions in the past 28 days; Albumin >35 g/L (3.5 g/dL); INR < 1.7 or PTT < 4 seconds above control
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance >50 mL/min
Liver function
Bilirubin ≤ 1.5 x ULN; AST & ALT ≤ 2.5 x ULN; if patient has liver metastases ≤ 5.0 x ULN
Cardiac function
QTc (Fridericia) ≤ 470 msec or ≤ 450 msec if history of additional risk factors for Torsade de Pointe
Patients must have adequate organ and marrow function measured within 7 days prior to enrollment including; Absolute neutrophils ≥ 1.5 x 10^9/L (1500/µL); Platelets ≥ 100 x 10^9/L (100 x 103/µL); Hemoglobin ≥90g/L* (10.0 g/dL) with no blood transfusions in the past 28 days. Bilirubin ≤ 1.5 x ULN (upper limit of normal)** AST & ALT ≤ 2.5 x ULN; if patient has liver metastases ≤ 5.0 x ULN Serum creatinine or: Creatinine clearance ≤ 1.5 x ULN / >50 mL/min Albumin >35 g/L (3.5 g/dL) INR/PTT INR < 1.7 or PTT < 4 seconds above control QTc (using the Fridericia correction calculation) >470 msec or >450 msec if history of additional risk factors for Torsade de Pointe (e.g. heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Chicago Medical Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify